New combo vaccine and immunotherapy tackles Hard-to-Treat breast cancer
Disease control
Completed
This early-phase trial tested a personalized cancer vaccine (SV-BR-1-GM) combined with an immunotherapy drug (retifanlimab) in 36 people with advanced breast cancer that had stopped responding to standard treatments. The vaccine is made from the patient's own tumor cells and aims…
Phase: PHASE1, PHASE2 • Sponsor: BriaCell Therapeutics Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC